Advanced ALK-positive NSCLC treatment has shifted from the first-generation TKI crizotinib to second-generation TKIs. Although proven clinically beneficial, acquired resistance develops eventually leading to clinical relapse. Lorlatinib, a third-generation, oral, reversible TKI, penetrates the CNS and overcomes the secondary resistance mutations in the ALK tyrosine kinase domain. It has greater efficacy over standard therapy in patients with ALK mutations.
1 In this context, Pfizer and Docplexus have organized a live webinar on 3 rd September 2021 at 7.00 PM . Renowned oncologists will discuss ‘Recent Advancement in the Management of ALK + mNSCLC' in this session. Post your queries and opinions, which will be discussed by the speakers during the session. ALK: Anaphylactic lymphoma kinase; CNS: Central Nervous System mNSCLC; metastatic non-small cell lung cancer; TKI: Tyrosine…
